|Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome|
NT Ihle, LA Byers, ES Kim, P Saintigny, JJ Lee, GR Blumenschein, A Tsao, ...
Journal of the National Cancer Institute 104 (3), 228-239, 2012
|Inhibition of B cell receptor signaling by ibrutinib in primary CNS lymphoma|
MS Lionakis, K Dunleavy, M Roschewski, BC Widemann, JA Butman, ...
Cancer Cell 31 (6), 833-843. e5, 2017
|A multiprotein supercomplex controlling oncogenic signalling in lymphoma|
JD Phelan, RM Young, DE Webster, S Roulland, GW Wright, M Kasbekar, ...
Nature 560 (7718), 387-391, 2018
|Targeting microRNAs with small molecules: from dream to reality|
S Zhang, L Chen, EJ Jung, GA Calin
Clinical Pharmacology & Therapeutics 87 (6), 754-758, 2010
|Small molecule compounds targeting miRNAs for cancer therapy|
PC Monroig, L Chen, S Zhang, GA Calin
Advanced drug delivery reviews 81, 104-116, 2015
|From laptop to benchtop to bedside: structure-based drug design on protein targets|
L Chen, J K Morrow, H T Tran, S S Phatak, L Du-Cuny, S Zhang
Current pharmaceutical design 18 (9), 1217-1239, 2012
|A critical assessment of combined ligand-and structure-based approaches to HERG channel blocker modeling|
L Du-Cuny, L Chen, S Zhang
Journal of chemical information and modeling 51 (11), 2948-2960, 2011
|Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screening|
GL Lin, KM Wilson, M Ceribelli, BZ Stanton, PJ Woo, S Kreimer, EY Qin, ...
Science Translational Medicine 11 (519), 2019
|Novel insights of structure-based modeling for RNA-targeted drug discovery|
L Chen, GA Calin, S Zhang
Journal of chemical information and modeling 52 (10), 2741-2753, 2012
|Recent development of anticancer therapeutics targeting Akt|
J K Morrow, L Du-Cuny, L Chen, E J Meuillet, E A Mash, G Powis, ...
Recent patents on anti-cancer drug discovery 6 (1), 146-159, 2011
|An OpenData portal to share COVID-19 drug repurposing data in real time|
KR Brimacombe, T Zhao, RT Eastman, X Hu, K Wang, M Backus, ...
|Heparan sulfate assists SARS-CoV-2 in cell entry and can be targeted by approved drugs in vitro|
Q Zhang, CZ Chen, M Swaroop, M Xu, L Wang, J Lee, AQ Wang, ...
Cell Discovery 6 (1), 1-14, 2020
|Glypican‐3‐Specific Antibody Drug Conjugates Targeting Hepatocellular Carcinoma|
Y Fu, DJ Urban, RR Nani, YF Zhang, N Li, H Fu, H Shah, AP Gorka, ...
Hepatology 70 (2), 563-576, 2019
|Matrix screen identifies synergistic combination of PARP inhibitors and nicotinamide phosphoribosyltransferase (NAMPT) inhibitors in Ewing sarcoma|
CM Heske, MI Davis, JT Baumgart, K Wilson, MV Gormally, L Chen, ...
Clinical Cancer Research 23 (23), 7301-7311, 2017
|Transcribed ultraconserved region 339 promotes carcinogenesis by modulating tumor suppressor microRNAs|
I Vannini, PM Wise, KB Challagundla, M Plousiou, M Raffini, E Bandini, ...
Nature communications 8 (1), 1-19, 2017
|Novel inhibitors induce large conformational changes of GAB1 pleckstrin homology domain and kill breast cancer cells|
L Chen, L Du-Cuny, S Moses, S Dumas, Z Song, AH Rezaeian, HK Lin, ...
PLoS Comput Biol 11 (1), e1004021, 2015
|Synergistic and Antagonistic Drug Combinations against SARS-CoV-2|
T Bobrowski, L Chen, RT Eastman, Z Itkin, P Shinn, CZ Chen, H Guo, ...
Molecular Therapy 29 (2), 873-885, 2021
|Comprehensive modeling and discovery of mebendazole as a novel TRAF2-and NCK-interacting kinase inhibitor|
Z Tan, L Chen, S Zhang
Scientific reports 6 (1), 1-10, 2016
|Characterization of clinically used oral antiseptics as quadruplex-binding ligands|
DR Calabrese, K Zlotkowski, S Alden, WM Hewitt, CM Connelly, ...
Nucleic acids research 46 (6), 2722-2732, 2018
|Mutation Profiles in Glioblastoma 3D Oncospheres Modulate Drug Efficacy|
KM Wilson, LA Mathews-Griner, T Williamson, R Guha, L Chen, P Shinn, ...
SLAS TECHNOLOGY: Translating Life Sciences Innovation 24 (1), 28-40, 2019